Pediatric Nephrology

, Volume 27, Issue 11, pp 2031–2038

Cystinuria: mechanisms and management

Review

Abstract

Cystinuria is a relatively uncommon cause of pediatric stone disease, but has significant morbidity if not properly controlled because of its significant stone recurrence rate. Cystinuria is caused by the inability of the renal tubules to reabsorb filtered cystine, which is poorly soluble at a typical urine pH <7. Although many advances have been made in the understanding of the genetic and physiological basis of cystinuria, the cornerstones of treatment still involve stone prevention with dietary measures and pharmacological therapy, coupled with surgical interventions for stone removal. Pharmacological treatments can carry significant side effects that must be monitored and can limit therapy as well as impede compliance. Most patients will require surgical intervention for stone removal, although compliance with prevention strategies reduces the need for intervention.

Keywords

Cystinuria Kidney stones Genetic Stone prevention Pharmacologic Therapy Surgical therapy 

References

  1. 1.
    Knoll T, Zollner A, Wendt-Nordahl G, Michel MS, Alken P (2005) Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up. Pediatr Nephrol 20:19–24PubMedCrossRefGoogle Scholar
  2. 2.
    Mattoo A, Goldfarb DS (2008) Cystinuria. Semin Nephrol 28:181–191PubMedCrossRefGoogle Scholar
  3. 3.
    Rogers A, Kalakish S, Desai RA, Assimos DG (2007) Management of cystinuria. Urol Clin North Am 34:347–362PubMedCrossRefGoogle Scholar
  4. 4.
    Goodyer P (2004) The molecular basis of cystinuria. Nephron Exp Nephrol 98:e45–e49PubMedCrossRefGoogle Scholar
  5. 5.
    Dello Strologo L, Pras E, Pontesilli C, Beccia E, Ricci-Barbini V, de Sanctis L, Ponzone A, Gallucci M, Bisceglia L, Zelante L, Jimenez-Vidal M, Font M, Zorzano A, Rousaud F, Nunes V, Gasparini P, Palacin M, Rizzoni G (2002) Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers: a need for a new classification. J Am Soc Nephrol 13:2547–2553PubMedCrossRefGoogle Scholar
  6. 6.
    Worcester EM, Coe FL, Evan AP, Parks JH (2006) Reduced renal function and benefits of treatment in cystinuria vs other forms of nephrolithiasis. BJU Int 97:1285–1290PubMedCrossRefGoogle Scholar
  7. 7.
    Coe FL, Evan AP, Worcester EM, Lingeman JE (2010) Three pathways for human kidney stone formation. Urol Res 38:147–160PubMedCrossRefGoogle Scholar
  8. 8.
    Evan AP, Coe FL, Lingeman JE, Shao Y, Matlaga BR, Kim SC, Bledsoe SB, Sommer AJ, Grynpas M, Phillips CL, Worcester EM (2006) Renal crystal deposits and histopathology in patients with cystine stones. Kidney Int 69:2227–2235PubMedCrossRefGoogle Scholar
  9. 9.
    Palacin M, Fernandez E, Chillaron J, Zorzano A (2001) The amino acid transport system b(o,+) and cystinuria. Mol Membr Biol 18:21–26PubMedGoogle Scholar
  10. 10.
    Dello Strologo L, Rizzoni G (2006) Cystinuria. Acta Paediatr Suppl 95:31–33PubMedCrossRefGoogle Scholar
  11. 11.
    Camargo SM, Bockenhauer D, Kleta R (2008) Aminoacidurias: clinical and molecular aspects. Kidney Int 73:918–925PubMedCrossRefGoogle Scholar
  12. 12.
    Font-Llitjos M, Jimenez-Vidal M, Bisceglia L, Di Perna M, de Sanctis L, Rousaud F, Zelante L, Palacin M, Nunes V (2005) New insights into cystinuria: 40 new mutations, genotype-phenotype correlation, and digenic inheritance causing partial phenotype. J Med Genet 42:58–68PubMedCrossRefGoogle Scholar
  13. 13.
    Brauers E, Hozyasz K, Golabek B, Slowik M, Schmidt C, Vester U, Zerres K, Eggermann T (2006) Identification of novel cystinuria mutations in pediatric patients. J Pediatr Urol 2:575–578PubMedCrossRefGoogle Scholar
  14. 14.
    Botzenhart E, Vester U, Schmidt C, Hesse A, Halber M, Wagner C, Lang F, Hoyer P, Zerres K, Eggermann T (2002) Cystinuria in children: distribution and frequencies of mutations in the SLC3A1 and SLC7A9 genes. Kidney Int 62:1136–1142PubMedCrossRefGoogle Scholar
  15. 15.
    Martens K, Jaeken J, Matthijs G, Creemers JW (2008) Multi-system disorder syndromes associated with cystinuria type I. Curr Mol Med 8:544–550PubMedCrossRefGoogle Scholar
  16. 16.
    Tiselius HG (2010) New horizons in the management of patients with cystinuria. Curr Opin Urol 20:169–173PubMedCrossRefGoogle Scholar
  17. 17.
    Barbey F, Joly D, Rieu P, Mejean A, Daudon M, Jungers P (2000) Medical treatment of cystinuria: critical reappraisal of long-term results. J Urol 163:1419–1423PubMedCrossRefGoogle Scholar
  18. 18.
    Geary DF, Schaefer F (2008) Comprehensive pediatric nephrology. Mosby/Elsevier, PhiladelphiaGoogle Scholar
  19. 19.
    Martins MC, Meyers AA, Whalley NA, Rodgers AL (2002) Cystine: a promoter of the growth and aggregation of calcium oxalate crystals in normal undiluted human urine. J Urol 167:317–321PubMedCrossRefGoogle Scholar
  20. 20.
    Sterrett SP, Penniston KL, Wolf JS Jr, Nakada SY (2008) Acetazolamide is an effective adjunct for urinary alkalization in patients with uric acid and cystine stone formation recalcitrant to potassium citrate. Urology 72:278–281PubMedCrossRefGoogle Scholar
  21. 21.
    Jaffe IA (1986) Adverse effects profile of sulfhydryl compounds in man. Am J Med 80:471–476PubMedCrossRefGoogle Scholar
  22. 22.
    Rumsby PC, Shepherd DM (1981) The effect of penicillamine on vitamin B6 function in man. Biochem Pharmacol 30:3051–3053PubMedCrossRefGoogle Scholar
  23. 23.
    Tomono I, Abe M, Matsuda M (1973) Effect of penicillamine (a vitamin B6 antagonist) on pyridoxal enzymes. J Biochem 74:587–592PubMedGoogle Scholar
  24. 24.
    Dello Strologo L, Laurenzi C, Legato A, Pastore A (2007) Cystinuria in children and young adults: success of monitoring free-cystine urine levels. Pediatr Nephrol 22:1869–1873PubMedCrossRefGoogle Scholar
  25. 25.
    DeBerardinis RJ, Coughlin CR II, Kaplan P (2008) Penicillamine therapy for pediatric cystinuria: experience from a cohort of American children. J Urol 180:2620–2623PubMedCrossRefGoogle Scholar
  26. 26.
    Sloand JA, Izzo JL Jr (1987) Captopril reduces urinary cystine excretion in cystinuria. Arch Intern Med 147:1409–1412PubMedCrossRefGoogle Scholar
  27. 27.
    Coe FL, Clark C, Parks JH, Asplin JR (2001) Solid phase assay of urine cystine supersaturation in the presence of cystine binding drugs. J Urol 166:688–693PubMedCrossRefGoogle Scholar
  28. 28.
    Nakagawa Y, Asplin JR, Goldfarb DS, Parks JH, Coe FL (2000) Clinical use of cystine supersaturation measurements. J Urol 164:1481–1485PubMedCrossRefGoogle Scholar
  29. 29.
    Pietrow PK, Auge BK, Weizer AZ, Delvecchio FC, Silverstein AD, Mathias B, Albala DM, Preminger GM (2003) Durability of the medical management of cystinuria. J Urol 169:68–70PubMedCrossRefGoogle Scholar
  30. 30.
    Assimos DG, Leslie SW, Ng C, Streem SB, Hart LJ (2002) The impact of cystinuria on renal function. J Urol 168:27–30PubMedCrossRefGoogle Scholar
  31. 31.
    Landau EH, Shenfeld OZ, Pode D, Shapiro A, Meretyk S, Katz G, Katz R, Duvdevani M, Hardak B, Cipele H, Hidas G, Yutkin V, Gofrit ON (2009) Extracorporeal shock wave lithotripsy in prepubertal children: 22-year experience at a single institution with a single lithotriptor. J Urol 182:1835–1839PubMedCrossRefGoogle Scholar
  32. 32.
    Ahmed K, Khan MS, Thomas K, Challacombe B, Bultitude M, Glass J, Tiptaft R, Dasgupta P (2008) Management of cystinuric patients: an observational, retrospective, single-centre analysis. Urol Int 80:141–144PubMedCrossRefGoogle Scholar
  33. 33.
    Kim SC, Burns EK, Lingeman JE, Paterson RF, McAteer JA, Williams JC Jr (2007) Cystine calculi: correlation of CT-visible structure, CT number, and stone morphology with fragmentation by shock wave lithotripsy. Urol Res 35:319–324PubMedCrossRefGoogle Scholar
  34. 34.
    Rule AD, Bergstralh EJ, Melton LJ III, Li X, Weaver AL, Lieske JC (2009) Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol 4:804–811PubMedCrossRefGoogle Scholar
  35. 35.
    Rule AD, Krambeck AE, Lieske JC (2011) Chronic kidney disease in kidney stone formers. Clin J Am Soc Nephrol 6:2069–2075PubMedCrossRefGoogle Scholar
  36. 36.
    Wendt-Nordahl G, Sagi S, Bolenz C, Alken P, Michel MS, Knoll T (2008) Evaluation of cystine transport in cultured human kidney cells and establishment of cystinuria type I phenotype by antisense technology. Urol Res 36:25–29PubMedCrossRefGoogle Scholar
  37. 37.
    Rimer JD, An Z, Zhu Z, Lee MH, Goldfarb DS, Wesson JA, Ward MD (2010) Crystal growth inhibitors for the prevention of L-cystine kidney stones through molecular design. Science 330:337–341PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2012

Authors and Affiliations

  1. 1.Division of Pediatric Nephrology and HypertensionCincinnati Children’s Hospital Medical CenterCincinnatiUSA

Personalised recommendations